AtaCor Medical, a San Clemente, CA-based medical device company, raised $28M in Series C funding.
The round was led by Arboretum Ventures and included existing investors Longview Ventures, Hatteras Venture Partners, Catalyst Health Ventures, and BayMed Venture Partners.
The company intends to use the funds to support FDA submission for its extravascular temporary pacing lead system as well as completion of a pilot study for the third generation EV-ICD lead system.
Led by CEO Rick Sanghera, Atacor Medical is advancing cardiac pacing and defibrillation lead technology with its proprietary extravascular cardiac rhythm management system that provides benefits of traditional, transvenous implantable cardiac defibrillation and temporary pacing without placing leads or devices in the heart or vascular system; maintaining the integrity of the heart for future cardiac care needs.
Commenting on the news, Rick Sanghera said: “As we plan for our upcoming clinical and regulatory milestones, this investment supports efforts that will bring AtaCor’s novel products to patients.”
FinSMEs
25/04/2024